PT  - JOURNAL ARTICLE
AU  - CHRISTOPHER MÅNSSON
AU  - ANDERS NILSSON
AU  - JOZEF URDZIK
AU  - BRITT-MARIE KARLSON
TI  - The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer
AID  - 10.21873/anticanres.13827
DP  - 2019 Nov 01
TA  - Anticancer Research
PG  - 6193--6196
VI  - 39
IP  - 11
4099  - http://ar.iiarjournals.org/content/39/11/6193.short
4100  - http://ar.iiarjournals.org/content/39/11/6193.full
SO  - Anticancer Res2019 Nov 01; 39
AB  - Background/Aim: Carbohydrate antigen 19-9 (CA19-9) is a tumor marker for pancreatic cancer. Irreversible electroporation (IRE) is an experimental treatment modality for pancreatic cancer. The aim of this study was to evaluate whether percutaneous IRE lowers the CA19-9 level in pancreatic cancer and whether this correlates with improved overall survival. Patients and Methods: Seventy-one patients with locally advanced pancreatic cancer or local recurrence after resection were treated. Patients with missing data, metastatic disease and normal serum CA19-9 before IRE were excluded. This left 35 cases for analysis. Results: The median CA19-9 did not decrease in the cohort after IRE treatment (282 U/ml before versus 315 U/ml after; p=0.80). The 25th percentile of patients with the best CA19-9 response had improved overall survival compared to the 25th percentile with the worst response (mean 13.1 versus 8.1 months, respectively; p=0.01). Conclusion: IRE did not lower the level of CA19-9 in pancreatic cancer cases. However, a response in CA19-9 was correlated with improved survival.